Small Molecule Targeted Drug Research Institute Established
Release time:
2020-08-14
Small Molecule Targeted Drug Research Institute Established
News 9# July 13 On the morning of the 9th, the listing ceremony of Anhui Jianfeng Beika Pharmaceutical Small Molecule Targeted Drug Research Institute was held in the Dongzhi Economic Development Zone of Anhui Province.
Dongzhi County Party Secretary Li Mingyue, County Mayor Sheng Guoxing, Chairman of the Group Company and Chairman of the Pharmaceutical Company Jiang Xiaomeng, and Lu Wei, founder of Shanghai Beika Pharmaceutical Company and professor of the Institute of Medicine of the Chinese Academy of Sciences, jointly unveiled the institute (right picture).
Sheng Guoxing County Chief pointed out in his speech at the listing site that the establishment of Anhui Jianfeng Beika Pharmaceutical Small Molecule Targeted Drug Research Institute is an attempt and exploration to deepen innovation drive and carry out industry-university-research cooperation. He hopes that Jianfeng Group will continue to increase investment in funds and talents, integrate scientific research resources, give full play to the innovative advantages of the research institute, and build the small molecule targeted drug research institute into a research institute with strong academic atmosphere, close industry-university-research cooperation, and remarkable scientific and technological achievements. He asked the Dongzhi Economic Development Zone Management Committee and relevant units directly under the county to make every effort to serve and ensure the construction and operation of the research institute, and through the joint efforts of all parties, the Dongzhi Economic Development Zone will be built into a highland of scientific and technological innovation, so that the park will bloom with science and technology. Flowers, bear the fruit of industry. Jiang Xiaomeng, chairman of
group company, delivered a speech at the listing ceremony of the research institute. He said that Shanghai North Carolina Pharmaceutical Company is a holding subsidiary of Jianfeng Group. It is a high-tech enterprise in Shanghai, a "specialized and new" technology enterprise in Shanghai, and a "Shanghai patent pilot enterprise". It has an academician expert workstation and Songjiang District "Enterprise Technology Center", and has a number of "Shanghai High-tech Achievement Transformation Project" results. The products mainly include intermediates such as small molecule targeted and alkaloid anti-tumor drugs. The company takes Shanghai Beika as the research and development and market highland, and takes Jianfeng Beika Pharmaceutical as the link of technology and variety transformation. The research and development results and industrialization results are produced and sold by two factories of Anhui Xinbeika Chemical and Anhui Zhongwang Pharmaceutical, and a small molecule targeted drug manufacturing base is built in Dongto Economic Development Zone. In order to better develop small molecule targeted drugs, with the assistance of Dongzhi County Party Committee and Economic Development Zone, a small molecule targeted drug research institute was established to speed up the progress of scientific and technological innovation and technological transformation, and realize the industrialization of small molecule targeted drug products as soon as possible. At the same time, the Small Molecule Targeted Drug Research Institute will also rely on the technical support of three academicians and experts of Jianfeng Pharmaceutical and four postdoctoral workstations, and cooperate with the Chinese Academy of Sciences, China Pharmaceutical University, Fudan University, Shanghai Molecular Therapy and New Drug Creation Engineering Technology Research Center and other scientific research institutions to establish long-term industry-university-research cooperation, in accordance with the principle of "innovation, creation, creation" and strive to create "green environmental protection, top technology, for the benefit of human health" high-end scientific research institutions. After the opening ceremony of
, Li Mingyue, Secretary of Dongzhi county Party committee, was interviewed by Jinhua Daily. While congratulating Jianfeng group on the 23rd anniversary of its establishment 60#, he said that Dongzhi county government and relevant departments will give maximum support and service to the small molecule targeted drug research institute, and ensure the construction and operation of the research institute, We hope that the Institute can give full play to its advantages and strive to achieve remarkable results as soon. (Ni Yingzhen Zhang Feifei)
1000 . The structure of small molecule drugs has good spatial dispersion, and its chemical properties determine its good pharmaceutical properties and pharmacokinetic properties. Small molecule drugs are usually signal transduction inhibitors, which can specifically block the signal transduction pathway necessary for tumor growth and proliferation, so as to achieve the purpose of treatment.
Targeting ). The purpose is to target the drug or its carrier at a specific lesion site and to accumulate or release the active ingredient at the target site. Targeted preparations can make the drug form a relatively high concentration in the target area, thereby improving the efficacy of the drug while inhibiting toxic side effects and reducing the damage to normal tissues and cells.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page